Herpes simplex virus partially liquifies the tightly packed, gel-like interior of human cell nuclei to copy itself faster, a new study shows. The research centers on how the nucleus of each human cell ...

Pritelivir, an investigational antiviral drug for herpes simplex virus, demonstrated “superior efficacy” in healing lesions ...

Ongoing research aims to confirm the mechanism by which ICP4 fluidizes the nucleus, which could indicate specific targets to counter viral replication.

Pritelivir, an investigational antiviral for herpes simplex virus, demonstrated strong efficacy in a phase 3 trial, with 62.7% of immunocompromised patients achieving lesion healing. The ...

In a subgroup analysis of people living with HIV enrolled in PRIOH-1, pritelivir demonstrated superior lesion healing, achieving 61% complete ...

The incidence of neonatal herpes simplex virus (HSV) infections in the UK and Ireland increased dramatically over 15 years, and outcomes remained poor, with mortality and long-term neurologic ...

Three-phase treatment offers patients with HSV infections an alternative to perpetual antiviral management ROATAN, BAY ...

– ABI-5366 is currently being evaluated in ongoing Phase 1b clinical trial with interim proof-of-concept data expected in fall 2025 – SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ...

Inhibiting the herpes simplex virus type 1 viral enzyme uracil-DNA glycosylase reactivates the natural defense protein apolipoprotein B mRNA editing enzyme, catalytic polypeptide-1 (APOBEC1) in the ...